Celixir Ltd. - Cell Therapy Ltd and Stem Cell Medicines Blog

Celixir is one of the most sought after UK firms which are involved in the design and development of life changing regenerative medicines while working towards common objectives with certain collaborative partnerships. With that said, let’s take a look at some of the most talked about collaborations which Celixir has secured with some of the most recognized firms and institutions in the past decade. DAIICHI SANKYO Celixir has given the license for carrying on the marketing and distributing responsibilities of their revolutionary cardiac regeneration medicine to Daiichi Sankyo on May 2016. Going by the agreement, Daiichi Sankyo will take care for the development, regulatory and commercial activities for Celixir’s immune-modulatory progenitor cells across Japanese territory. Moreover, Celixir will still be responsible for the same operations within territories across rest of the world for Celixir stem cell therapy. INNOVATIVE CARDIOVASCULAR MEDICINES COLLABORATION Celixir has also for...

Celixir comes as a UK firm indulged in the discovery and development of life changing regenerative medicines and whilst working towards their common goals via collaborative partnerships. That said; let’s take a look at their collaborations with various recognized firms and institutions in the past few years. DAIICHI SANKYO Celixir has granted the Japan license for their innovative cardiac regeneration medicine to Daiichi Sankyo on May 2016. As per the agreement, Daiichi Sankyo will be taking care of all the development, regulatory and commercial activities regarding Celixir’s immunomodulatory progenitor cells within Japanese territory. On the other side, Celixir will be taking care of the worldwide rights for Celixir stem cells therapy for the rest of the world. INNOVATIVE CARDIOVASCULAR MEDICINES COLLABORATION Celixir has further formed the Innovative Cardiovascular Medicines Collaboration which includes global experts in cardiac research and clinical development, coming o...

Just days after the Cardiff-based cell therapy company Cell Therapy Ltd (CTL) signed an agreement with Japan’s Daiichi Sankyo, providing them with the rights to its heart failure drug Heartcel, the company’s chief executive, Ajan Reginald , got interviewed by one of the leading dailies. Heartcel, an immune-modulator progenitor (iMP), can be considered as one of the allogeneic celixir stem cells therapy which posses the power to redevelop the human heart. The same therapy has confirmed two-year MACE-free survival for all the tested patients in the Phase II clinical trial studying myocardial regeneration. As per the agreement, Daiichi Sankyo will take care of the development, regulatory approval and marketing of Heartcel in the Japanese territory, while CTL will still holds the rights for the rest of the world. Mr. Ajan Reginald , the co-founder of CTL, quoted that the deals comes as a future step towards accomplishing the global mission of bringing company’s life-saving dru...

Celixir (formerly known as Cell Therapy Ltd.) is a private British regenerative medicine company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need. Celixir , founded in 2009, is made up of a world-class team of scientists and biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche Global Head of Emerging Technologies, Ajan Reginald . Celixir’s unique platform technology allows us to adopt an ‘off-the-shelf’ approach to deliver regenerative medicines to patients. Website : http://www.celixir.com Headquarters : Cardiff, Wales Year Founded : 2009 Company Type : Privately Held Size : 11-50 employees Specialties : regenerative medicine, cell therapies, cardiovascular medicine, cellular research, stem cells